Summary: Gut microbiota has emerged as a determinant of cancer therapy efficacy, shaping immune responses both systemically and locally within the tumor microenvironment. In this piece, we discuss current insights into the mechanistic basis of these interactions, with a focus on type I interferon as a central mediator of microbiota-driven immune modulation.
Lam et al. (Fri,) studied this question.